Contract ABL HHSN272201800009I ALS3 GMP master cell bank production and formulation development
Ended Awarded Last action
- Contract number
- 75N93023F00002
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $443,276
Award facts
- Contract value 100% obligated
- $443,276.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $443,276 |
About this award
Advanced Bioscience Laboratories, Inc. (ABL) has been awarded a $443,276 delivery order under contract ABL HHSN272201800009I by the National Institute of Allergy and Infectious Diseases (NIAID) for ALS3 GMP Master Cell Bank Production and Formulation Development. The contract is structured as cost-plus-fixed-fee pricing with an ultimate completion date of March 31, 2026, and work will be performed in Potomac, Maryland. This delivery order represents a focused effort within ABL's broader relationship with NIAID and carries no set-aside designation, consistent with ABL's status as a large business contractor in the federal marketplace.
ABL brings extensive expertise in current Good Manufacturing Practice (cGMP) biologics manufacturing, cell banking, and formulation development—capabilities well-aligned with NIAID's mission to support the development of medical countermeasures for infectious diseases. The company maintains multiple substantial indefinite delivery vehicles with NIH institutes, including a $98.9 million IDV with NIAID for preclinical development support services. This specific delivery order represents a component of ABL's ongoing work supporting the agency's vaccine and therapeutic development initiatives, leveraging the contractor's specialized capabilities in producing and formulating master cell banks essential for scalable biopharmaceutical manufacturing.
Quick answers
Who was awarded contract 75N93023F00002?
75N93023F00002 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 26, 2023.
How much is contract 75N93023F00002 worth?
The government has obligated $443,276 on 75N93023F00002.
Is contract 75N93023F00002 an order under another contract?
Yes. 75N93023F00002 is a delivery order under 75N93018D00009, an indefinite delivery contract.
Was contract 75N93023F00002 competed?
The extent of competition for 75N93023F00002 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award